"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)"

drug protocol number
CSEG101A2301
drug sponsor
Novartis
drug study
Crizanlizumab
drug trial site
King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase